Madrigal is focused on developing therapeutics to improve the lives of patients with metabolic and fatty liver diseases.
Liver Disease β’ NASH β’ Metabolic Disease
51 - 200
π° $259M Post-IPO Equity on 2022-12
April 25
51 - 200
πΊπΈ United States β Remote
π° $259M Post-IPO Equity on 2022-12
β° Full Time
π΄ Lead
πΌ Legal
π½ H1B Visa Sponsor
April 24
51 - 200
πΊπΈ United States β Remote
π° $259M Post-IPO Equity on 2022-12
β° Full Time
π‘ Mid-level
π Senior
π§ QA Engineer
π½ H1B Visa Sponsor
April 24
51 - 200
πΊπΈ United States β Remote
π° $259M Post-IPO Equity on 2022-12
β° Full Time
π‘ Mid-level
π Senior
π¨βπΌ Executive Assistant
π½ H1B Visa Sponsor
April 11
51 - 200
πΊπΈ United States β Remote
π° $259M Post-IPO Equity on 2022-12
β° Full Time
π Senior
βοΈ Operations
π½ H1B Visa Sponsor